Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?

The current therapeutic landscape of luminal human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC) is fundamentally evolving, particularly in the advent of molecularly targeted therapies, such as inhibitors of mammalian target of rapamycin and cyclin-dependent kinas...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Lorenzo, McCartney, Amelia, Risi, Emanuela, Malorni, Luca, Biganzoli, Laura, Di Leo, Angelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295674/
https://www.ncbi.nlm.nih.gov/pubmed/30574210
http://dx.doi.org/10.1177/1758835918815591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295674/
https://www.ncbi.nlm.nih.gov/pubmed/30574210
http://dx.doi.org/10.1177/1758835918815591

Ejemplares similares